Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUB-030 in Advanced Solid Tumors
NCT06657222Phase 2Recruiting
- Sponsor
- Tubulis
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of GS-8823 in solid tumor, head and neck squamous cell carcinoma (HNSCC), small cell lung cancer (SCLC) and 3 more (2 arms), sponsored by Tubulis. Primary endpoint: Maximum Tolerated Dose. Started Dec 2024; status: recruiting.
02
Drugs
GS-8823
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06657222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657222.